EFEITO DA SEMAGLUTIDA NO TRATAMENTO DA OBESIDADE E SÍNDROME METABÓLICA

Abstract

Metabolic syndrome represents a set of interrelated disorders, such as insulin resistance, hypertension, dyslipidemia, and central obesity, which significantly increase the risk of cardiovascular diseases and type 2 diabetes. In recent years, the use of semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a new therapeutic approach capable of promoting weight reduction and improving glycemic control. This study aimed to analyze the risks and benefits of semaglutide in the treatment of metabolic syndrome, emphasizing its therapeutic efficacy and potentialadverse effects. This is a literature review conducted through the analysis of recent scientific articles available in national and international databases. The results showed that semaglutide promotes significant weight loss, improvement in cardiometabolic parameters, and good tolerability, although some gastrointestinal effects, such as nausea, vomiting, diarrhea, and constipation, are frequently reported. It is concluded that the drug represents an important advance in the treatment of metabolic diseases, provided that it is used rationally, with multiprofessional monitoring and expanded access policies. Further studies are needed to evaluate its long-term effects and optimize its clinical use.